Jan 10, 2022 / 08:45PM GMT
Tycho W. Peterson - JPMorgan Chase & Co, Research Division - Senior Analyst
All right. Good afternoon, everybody. I'm Tycho Peterson from the Life Science team. It's my pleasure to introduce our next company this afternoon, Illumina. Just a quick reminder, there's a Submit Question feature on the website if you want questions answered during the Q&A. And with that, I'll turn it over to Francis.
Francis A. deSouza - Illumina, Inc. - CEO & Director
Thank you, Tycho, and the JPMorgan team for hosting us. Good afternoon, everyone. Thank you for joining us. Before we begin, I'd like to remind you that our presentation includes non-GAAP financial measures and forward-looking statements. Reconciliations to GAAP measures are included in our presentation on our Investor Relations website. Please refer to our SEC filings for a full presentation of risks.
I'll start with who we are and what we do. Our mission at Illumina is to improve human health by unlocking the power of the genome. Our sequencers enable researchers in academic, government and
Illumina Inc at JPMorgan Healthcare Conference Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot